SCAP and metabolic dysfunction-associated steatotic liver disease: The prevalence of MASLD in the obese/overweight population is as high as 79%, emphasizing the urgent need to unfold promising therapeutics targeting critical mediators, such as SCAP/SREBP, involved in the pathogenesis of MASLD [9].